Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Allogene Therapeutics Inc’s stock clocked out at $1.94, up 2.65% from its previous closing price of $1.89. In other words, the price has increased by $2.65 from its previous closing price. On the day, 5.52 million shares were traded. ALLO stock price reached its highest trading level at $2.1 during the session, while it also had its lowest trading level at $1.88.
Ratios:
To gain a deeper understanding of ALLO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.35 and its Current Ratio is at 9.35. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
On May 31, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $11.Piper Sandler initiated its Overweight rating on May 31, 2024, with a $11 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 14 ’25 when Beneski Benjamin Machinas bought 5,488 shares for $1.97 per share.
Chang David D bought 46,668 shares of ALLO for $91,469 on Mar 14 ’25. On Feb 18 ’25, another insider, MESSEMER DEBORAH M., who serves as the Director of the company, sold 13,313 shares for $2.43 each. As a result, the insider received 32,351 and left with 144,316 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 421494112 and an Enterprise Value of 219773584. For the stock, the TTM Price-to-Sale (P/S) ratio is 10537.25 while its Price-to-Book (P/B) ratio in mrq is 0.88. Its current Enterprise Value per Revenue stands at 9989.709 whereas that against EBITDA is -0.901.
Stock Price History:
The Beta on a monthly basis for ALLO is 0.86, which has changed by -0.53809524 over the last 52 weeks, in comparison to a change of 0.09506309 over the same period for the S&P500. Over the past 52 weeks, ALLO has reached a high of $4.89, while it has fallen to a 52-week low of $1.32. The 50-Day Moving Average of the stock is -0.34%, while the 200-Day Moving Average is calculated to be -19.07%.
Shares Statistics:
It appears that ALLO traded 5.38M shares on average per day over the past three months and 3284870 shares per day over the past ten days. A total of 209.50M shares are outstanding, with a floating share count of 134.60M. Insiders hold about 35.80% of the company’s shares, while institutions hold 65.94% stake in the company. Shares short for ALLO as of 1740700800 were 39095990 with a Short Ratio of 7.26, compared to 1738281600 on 32048327. Therefore, it implies a Short% of Shares Outstanding of 39095990 and a Short% of Float of 26.22.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of Allogene Therapeutics Inc (ALLO).The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.25 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$1.12 and -$1.38 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$1.37, with 6.0 analysts recommending between -$1.06 and -$1.51.
